PTC Therapeutics price target raised to $82 from $70 at RBC Capital

RBC Capital raised the firm’s price target on PTC Therapeutics (PTCT) to $82 from $70 and keeps an Outperform rating on the shares after its Q3 earnings beat. The company’s Sephience launch appears to be off to an excellent start, likely surpassing the growing expectations into the quarter, and with signals supporting good near/medium-term durability, the analyst tells investors in a research note.